Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyper-sialylated human IgG m234
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Hyper-sialylated human IgG m234** is an engineered hyper-sialylated form of human immunoglobulin G designed to enhance anti-inflammatory effects beyond standard IVIg therapy. It features increased sialylation on the Fc domain, which upregulates inhibitory FcγRIIb on effector cells like macrophages and B cells, reduces binding to activating Fcγ receptors, and attenuates proinflammatory responses. Developed by Momenta Pharmaceuticals (acquired by Janssen/Johnson & Johnson), it aims to treat autoimmune diseases such as immune thrombocytopenia purpura (ITP) at lower doses with improved efficacy and tolerability compared to conventional high-dose IVIg.
- Other names
- M254M-254M 254
02
Targets
DC-SIGN (Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin)FCGR2B (Fc gamma receptor IIB)FCER2 (Low affinity immunoglobulin epsilon fc receptor)SIGNR1 (CD209 antigen-like protein B)
Beyond the preview
Go deeper on Hyper-sialylated human IgG m234.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyper-sialylated human IgG m234.